Cellusion exhibits at the Japan Pavilion organized by JETRO
at the 2024 BIO International Convention
Cellusion Inc. (CEO: Shin Hatou, M.D. Ph.D., “Cellusion”), a deep tech start-up developing iPS cell-derived corneal endothelial cell substitute for the treatment of bullous keratopathy, announced that the company will participate in the 2024 BIO International Convention to be held from June 3 to 6, 2024, in San Diego, California, USA.
This convention is one of the world’s largest and most comprehensive event for biotechnology, representing the full ecosystem of biotech. More than 20,000 life science-related industry leaders from around the world gather to discover new opportunities and promising partnerships.
Under the support program of the Japan External Trade Organization (“JETRO”), Cellusion will be exhibiting at the Japan Pavilion booth, which JETRO has set up to support overseas business operations of Japanese companies.
[Cellusion Exhibit Information]
2024 BIO International Convention (BIO 2024): https://convention.bio.org/
Dates: Monday, June 3 – Thursday, June 6, 2024
Venue: San Diego Convention Center (111 W Harbor Drive, San Diego, CA 92101)
Section: Booth #4421, JETRO Japan Pavilion
By expanding the network through participation in international events, Cellusion will promote the global development of its lead program, the development of corneal endothelial regenerative medicine using iPS cells for the treatment of bullous keratopathy.
[About CLS001]
CLS001 is alternative cell to corneal endothelial cells produced by efficiently differentiating iPS cells, which can be differentiated into various types of cells, based on Cellusion’s proprietary technique. Cellusion is promoting the development of CLS001 as a therapeutic regenerative medicine product for bullous keratopathy, which accounts for more than half of the corneal transplant cases, by combining “CECSi Cells* made from iPS cells with excellent proliferative properties” and “a simple injection cell delivery procedure without needs of human expertise.” Cellusion is also advancing preparations for company-sponsored clinical trials in Japan, as well as preparations for global clinical trials.
*CECSi Cells: Corneal Endothelial Cell Substitute from iPS Cells”
[About Bullous Keratopathy]
Bullous keratopathy is a rare disease that occurs when corneal endothelial cells, which control the amount of fluid at the inner-most part of the cornea, decrease due to eye surgery of cataract or genetic factors, resulting in problems with their function, whereby the cornea becomes swollen and causes visual impairment due to opacity. This disease is progressive and may lead to blindness if left untreated. Today, this disease can only be treated by transplanting normally functioning corneal endothelial cells via corneal transplant. Nevertheless, as with other organ transplants, corneal transplants are also facing a serious problem of donor shortage. In Japan alone, it is estimated that there are about 10,000 patients, and in the global survey conducted in 2013 it was reported that approximately 13 million patients are waiting for corneal transplants.
[About Cellusion]
Cellusion is a regenerative medicine start-up originating from the Department of Ophthalmology, Keio University School of Medicine, with “Regenerating Human Potential” as its mission and “More Freedom and More Smiles to the World” as its vision. Based on patented technology such as its proprietary technique of efficiently producing corneal endothelial substitute cell from iPS cells, Cellusion is promoting R&D aimed at meeting medical needs from the perspective of “patient centricity” by leveraging cutting-edge regenerative medicine technology, including the lead program CLS001 that aims to meet the global corneal transplant demands.
Company: Cellusion Inc.
CEO: Shin Hatou, M.D., Ph.D.
Headquarters: Harumi Center bldg. 5th floor, 2-5-24 Harumi, Chuo, Tokyo 104-0053, JAPAN
Founded: January 2015
URL: https://cellusion.jp/en/
For further information: please ask us through the contact form on our website.
